Strides Pharma debuts with stellar ESG rating of 76/100 in S&P Global CSA 2024
Bangalore: Strides Pharma Science Limited has announced that the
Company has received an ESG score of 76/100 and CSA score of 75/100 in the Corporate Sustainability
Assessment (CSA) Annual Review (vide report dated 20th January, 2025) for its debut submission.
With this achievement, Strides has secured a
position in the 94th percentile among its peers in the DRG Global Pharmaceuticals industry. On Customer
Relations, the Company achieved 100th percentile. “The Company has demonstrated exceptional performance by achieving an ESG score of 76/100, driven by
the Social and Goverence Dimensions, which carry the highest weightage, securing the 97th percentile. In
Environment dimension, the Company attained a commendable 87th percentile,” Strides stated.
Arun Kumar, Founder & Executive Chairperson, and Mr. Badree Komandur, MD & Group CEO,
commented, “We are proud to announce that we have received an industry-leading ESG rating from S&P
Global on our debut submission. This accomplishment underscores our unwavering commitment to
sustainability. It validates our dedication to responsible business practices and reinforces our ongoing efforts
to integrate ESG principles across our business operations. As we continue to strengthen and expand our
ESG initiatives, we remain focused on creating a lasting, positive impact for all our stakeholders.”
“This outstanding performance is underpinned by key material drivers, including Contribution to Societal
Healthcare, Human Capital Management, and Corporate Governance, which continue to be pivotal in
shaping the company’s sustainability excellence. We remain committed to maintaining and further
enhancing our ESG performance, striving to set new benchmarks in sustainability and responsible business
practices in the years ahead,” the Company added.
Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited
(532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the
regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donorfunded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and
two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company
focuses on “difficult to manufacture” products sold in over 100 countries.
Read also: Strides Pharma Science arm gets USFDA nod for Acetaminophen and Ibuprofen Tablets
